Australian generics group releases new edition of Code of Practice for public consultation

26 September 2013

Australia’s Generic Medicines Industry Association (GMiA) this morning released the draft third edition of the GMiA Code of Practice, which incorporates a number of new amendments. The association is encouraging feedback from stakeholders on this draft document by the end of October.

The GMiA draft includes the recommendations from the Working Group on Promotion of Therapeutic Products as reported to the then Parliamentary Secretary, Catherine King, in March 2011. The composition of the Code Complaint Committee has been adjusted to increase the independence of the committee. All industry representatives on the committee have been removed.

Members will continue to report on educational events and non-price benefits. The timing of the preparation report has been streamlined. Reports will now cover the period July 1 to June 30.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >